Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain Tumors

Chenevert, Thomas L.; Stegman, Lauren D.; Taylor, Jeremy M. G.; Robertson, Patricia L.; Greenberg, Harry S.; Rehemtulla, Alnawaz; Ross, Brian D.

doi:10.1093/jnci/92.24.2029

Cited by 634 publications

(507 citation statements)

References 34 publications

Supporting

Mentioning

484

Contrasting

Unclassified

Order By: Relevance

“…On a patient-bypatient basis, fDM had a sensitivity and a specificity of 100%. This current study significantly extends earlier work accomplished in rodent brain tumors (13,20,21,(23)(24)(25)28) and the preliminary clinical observations in patients with brain and other cancer types (28)(29)(30)(31)(32). The advancement reported in this study was achieved by using coregistered MRI datasets along with thresholding allowing for quantification of change in treatment-induced tumor diffusion values.…”

Section: Discussionsupporting

confidence: 85%

“…However, clinical utility of this approach has been hampered because of tumor heterogeneity and suboptimal methods of digital image analysis (28)(29)(30)(31)(32). Furthermore, although these preliminary studies have shown correlations between ADC change and tumor response, a definitive study demonstrating the ability of diffusion MRI to predict response has not been reported.…”

mentioning

confidence: 99%

“…We investigated whether diffusion MRI could be used to provide early detection of the therapeutic response of malignant brain tumors in humans as was observed in rodent brain tumors (13,28). In this study, we prospectively compared tumor diffusion values at 3 weeks after initiation of therapy with pretreatment images to quantitate therapy-induced changes in ADC.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Moffat

Chenevert

Lawrence

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

586

477

View full text Add to dashboard Cite

Assessment of radiation and chemotherapy efficacy for brain cancer patients is traditionally accomplished by measuring changes in tumor size several months after therapy has been administered. The ability to use noninvasive imaging during the early stages of fractionated therapy to determine whether a particular treatment will be effective would provide an opportunity to optimize individual patient management and avoid unnecessary systemic toxicity, expense, and treatment delays. We investigated whether changes in the Brownian motion of water within tumor tissue as quantified by using diffusion MRI could be used as a biomarker for early prediction of treatment response in brain cancer patients. Twenty brain tumor patients were examined by standard and diffusion MRI before initiation of treatment. Additional images were acquired 3 weeks after initiation of chemo-and͞or radiotherapy. Images were coregistered to pretreatment scans, and changes in tumor water diffusion values were calculated and displayed as a functional diffusion map (fDM) for correlation with clinical response. Of the 20 patients imaged during the course of therapy, 6 were classified as having a partial response, 6 as stable disease, and 8 as progressive disease. The fDMs were found to predict patient response at 3 weeks from the start of treatment, revealing that early changes in tumor diffusion values could be used as a prognostic indicator of subsequent volumetric tumor response. Overall, fDM analysis provided an early biomarker for predicting treatment response in brain tumor patients. diffusion MRI ͉ therapeutic response

show abstract

Section: Discussionsupporting

confidence: 85%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Moffat

Chenevert

Lawrence

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

586

477

View full text Add to dashboard Cite

show abstract

“…139 Moreover, diffusion-weighted MRI detects therapy-induced water diffusion changes and has been suggested to provide an early surrogate marker for quantification of treatment response. 140 It was found that low values for the ADC indicating high tissue viability imply better response to radiotherapy, whereas high ADC values indicating necrosis correlate with poorer response. 141 Assessment of ADC ratios from tumor and contralateral control regions were also useful in the differentiation of radiation effects (high ADC ratios) from tumor recurrence or progression (low ADC ratios).…”

Section: Imaging For Determination Of Treatment Effect Tumor Progresmentioning

confidence: 98%

Imaging in neurooncology

et al. 2005

View full text Add to dashboard Cite

“…At the interface of these fields are applications that employ a variety of imaging modalities, including magnetic resonance imaging (MRI) (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16), the use of radionuclide tracers in positron emission tomography (PET) and single photon emission tomography (SPECT) (16 -25), x-ray computed tomography (CT) (26,27), and optical methods (2,5,28 -40). This nascent area of investigation is rapidly gaining acceptance in diverse fields, such as cancer biology, immunology, gene therapy, and microbiology.…”

mentioning

confidence: 99%

It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology

Contag

Ross

2002

Magnetic Resonance Imaging

254

189

View full text Add to dashboard Cite

Among the newly described tools that enable analyses of cellular and molecular events in living animals, in vivo bioluminescence imaging (BLI) offers important opportunities for investigating a wide variety of disease processes. BLI utilizes luciferase as an internal biological light source that can be genetically programmed to noninvasively "report" the presence or activation of specific biological events. Applications of BLI have included the use of luciferase to demonstrate expression of cell-and tissue-specific promoters, label cell populations, guide detection by other imaging modalities, and detect protein-protein interaction. These applications of BLI technology have allowed quantitative measurements of tumor burden and treatment response, immune cell trafficking, and detection of gene transfer. Spatiotemporal information can be rapidly obtained in the context of whole biological systems in vivo, which can accelerate the development of experimental therapeutic strategies. This paper provides a review of the biological applications in which in vivo BLI has been utilized to nondestructively monitor biological processes in intact small animal models, and highlights some of the advancements that will increase the versatility of BLI as a molecular imaging tool.

show abstract

Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain Tumors

Abstract: These results suggest that diffusion MRI will provide an early surrogate marker for quantification of treatment response in patients with brain tumors.

Cited by 634 publications

References 34 publications

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Imaging in neurooncology

It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology

Contact Info

Product

Resources

About